# Study of Milademetan in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)

> **NCT03671564** · PHASE1 · COMPLETED · sponsor: **Daiichi Sankyo Co., Ltd.** · enrollment: 14 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Milademetan

## Key facts

- **NCT ID:** NCT03671564
- **Lead sponsor:** Daiichi Sankyo Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-23
- **Primary completion:** 2019-09-11
- **Final completion:** 2019-09-11
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2023-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03671564

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03671564, "Study of Milademetan in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03671564. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*